Allworth Financial LP Has $3.46 Million Stock Position in Pfizer Inc. (NYSE:PFE)

Allworth Financial LP grew its position in Pfizer Inc. (NYSE:PFE) by 12.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 132,932 shares of the biopharmaceutical company’s stock after purchasing an additional 15,177 shares during the quarter. Allworth Financial LP’s holdings in Pfizer were worth $3,458,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of PFE. Principal Securities Inc. boosted its stake in Pfizer by 1.9% during the fourth quarter. Principal Securities Inc. now owns 84,689 shares of the biopharmaceutical company’s stock worth $2,247,000 after acquiring an additional 1,609 shares in the last quarter. bLong Financial LLC bought a new position in Pfizer during the fourth quarter worth $421,000. TigerOak Management L.L.C. bought a new position in Pfizer during the fourth quarter worth $837,000. Roxbury Financial LLC bought a new position in Pfizer during the fourth quarter worth $399,000. Finally, Manchester Capital Management LLC boosted its stake in Pfizer by 7.6% during the fourth quarter. Manchester Capital Management LLC now owns 47,137 shares of the biopharmaceutical company’s stock worth $1,251,000 after acquiring an additional 3,326 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Wolfe Research assumed coverage on shares of Pfizer in a research note on Friday, November 15th. They set an “underperform” rating and a $25.00 target price on the stock. StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Citigroup dropped their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. UBS Group dropped their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Wednesday, October 23rd. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Stock Performance

Shares of PFE stock opened at $25.50 on Tuesday. The firm has a 50-day moving average of $26.28 and a 200-day moving average of $27.54. The company has a market cap of $144.48 billion, a P/E ratio of 18.08, a P/E/G ratio of 0.64 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter last year, the company posted $0.10 earnings per share. The firm’s quarterly revenue was up 24.7% compared to the same quarter last year. Equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.75%. The ex-dividend date of this dividend is Friday, January 24th. This is an increase from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio (DPR) is 121.99%.

Insider Transactions at Pfizer

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The stock was purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.